摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-tert-butoxycarbonyl (-)-Geissman-Waiss lactone | 118462-78-5

中文名称
——
中文别名
——
英文名称
N-tert-butoxycarbonyl (-)-Geissman-Waiss lactone
英文别名
tert-butyl (3aS,6aS)-2-oxo-3a,5,6,6a-tetrahydro-3H-furo[3,2-b]pyrrole-4-carboxylate
N-tert-butoxycarbonyl (-)-Geissman-Waiss lactone化学式
CAS
118462-78-5
化学式
C11H17NO4
mdl
——
分子量
227.26
InChiKey
STOSVFIZVJTPBI-YUMQZZPRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    55.8
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Expedient syntheses of (+)-cis-(2R,3S)-3-hydroxyproline and (–)-(1S,5S)-2-oxa-6-azabicyclo[3.3.0]octan-3-one (the Geissman–Waiss lactone): formal enantioselective syntheses of (–)-retronecine and related pyrrolizidine alkaloids
    作者:Jeremy Cooper、Peter T. Gallagher、David W. Knight
    DOI:10.1039/c39880000509
    日期:——
    (6)(diastereoisomeric excess > 99%cis; enantiomeric excess, e.e., 80%); subsequent hydrolysis and crystallisation gives (+)-cis-(2R,3S)-3-hydroxyproline (7)(93% e.e.) which has been homologated to the bicyclic lactones (10) and (11), precursors of ()-retronecine, (+)-platynecine, ()-croalbinecine and related pyrrolizidines.
    酵母还原酮脯酸(5)得到羟基脯酸衍生物(6)(非对映异构体过量> 99%顺式;对映异构体过量,ee,80%);和(对映体过量,ee,80%)。随后解和结晶,得到(+)-顺式-(2 R,3 S)-3-羟基脯氨酸(7)(93%ee),已与(-)的前体双环内酯(10)和(11)同源。 )-维甲酸,(+)-亚胺,(-)-croalbinecine和相关的吡咯嗪核苷。
  • Kouyama, Takafumi; Matsunaga, Hirofumi; Ishizuka, Tadao, Heterocycles, 1997, vol. 44, # 1, p. 479 - 486
    作者:Kouyama, Takafumi、Matsunaga, Hirofumi、Ishizuka, Tadao、Kunieda, Takehisa
    DOI:——
    日期:——
  • Asymmetric intramolecular Pd(II)-catalysed amidocarbonylation of unsaturated amino alcohols
    作者:Peter Koóš、Ivan Špánik、Tibor Gracza
    DOI:10.1016/j.tetasy.2009.10.024
    日期:2009.12
    The first example of an asymmetric carbonylative bicyclisation of racemic N-protected 1-amino-pent-4-ene-3-ols (+/-)-1 catalysed by palladium(II) with chiral bis(oxazoline) ligands was investigated. The kinetic resolution of (+/-)-1 in the presence of chiral catalyst, p-benzoquinone in acetic acid under carbon monoxide atmosphere afforded enantiomerically enriched derivatives of 2-oxa-6-azabicyclo[3.3.0]octan-3-ones (R,R)-2 and (S,S)-2, respectively. (C) 2009 Elsevier Ltd. All rights reserved.
  • Alternative Synthesis of (-)-Geissman-Waiss Lactone, a Key Intermediate of Necine Bases
    作者:Toshio Honda、Sae Matsumoto
    DOI:10.3987/com-05-s(k)29
    日期:——
    A facile synthetic route to (-)-Geissman-Waiss lactone, a key intermediate of necine bases, was established by employing ring closing metathesis (RCM), followed by intramolecular Michael reaction of the resulting a,p-unsaturated lactone, as the key steps.
  • COOPER, JEREMY;GALLAGHER, PETER T.;KNIGHT, DAVID W., J. CHEM. SOC. CHEM. COMMUN.,(1988) N 8, 509-510
    作者:COOPER, JEREMY、GALLAGHER, PETER T.、KNIGHT, DAVID W.
    DOI:——
    日期:——
查看更多

同类化合物

顺式六氢呋喃[2,3-C]吡咯 顺式-六氢呋喃并[3,4-C]吡咯 甲基4-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸酯 氮杂环丁烷并[1,2-a]呋喃并[2,3-c]吡咯 夫沙瑞汀A 呋喃并吡咯甲酸 吡喃并[3,4-b]吡咯-2,7-二羧酸,1-乙酰基-1,5-二氢-5-羰基-,二乙基酯 六氢-1H-呋喃并[3,4-c]吡咯 六氢-1H-呋喃并[3,4-C]吡咯 八氢-呋喃并[3,2-c]吡啶 乙基4,6-二氢-5H-呋喃并[2,3-c]吡咯-5-羧酸酯 6H-呋喃并[2,3-b]吡咯-5-羧酸甲酯 6-甲基-6H-呋喃并[2,3-b]吡咯-5-羧酸 6-甲基-6H-呋喃并[2,3-b]吡咯-5-甲酰肼 5-(叔-丁氧羰基)-5,6-二氢-4H-呋喃并[2,3-C]吡咯-3-羧酸 4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 4H-呋喃并[3,2-b]吡咯-5-羧酸,2-甲酰基-,甲基酯 4H-呋喃并[3,2-b]吡咯 4H-呋喃并[3,2-B!吡咯-5-羧酸甲酯 4-甲基呋喃[3,2-b]吡咯-5-羧酸乙酯 4-甲基-4H-呋喃并[3,2-b]吡咯 4-甲基-4H-呋喃并[3,2-B]吡咯-5-甲酸 365-苄基六氢-1H-呋喃[34-c]吡咯 3-溴-4H-呋喃并[3,2-b]吡咯-5-羧酸 3-溴-4H-呋喃并[3,2-b]吡咯-5-甲酸乙酯 2-苯基-4H-呋喃并[3,2-b]吡咯-5-羧酸 2-甲酰基-6-甲基-6H-呋喃并[2,3-b]吡咯-5-羧酸 2-甲酰基-4-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸 2-溴-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-溴-4H-呋喃并[3,2-B]吡咯-5-羧酸 2-(4-甲氧基苯基)-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-(4-甲氧基苯基)-4H-呋喃并[3,2-b]吡咯-5-羧酸 2,3,3A,4-四氢-5H-呋喃并[3,2-b]吡咯-5-酮 1-(4H-呋喃并[3,2-b]吡咯-4-基)乙酮 1-(2-甲基-4H-呋喃并[3,2-b]吡咯-4-基)乙酮 (9ci)-1-甲基-1H-呋喃并[3,4-b]吡咯-4,6-二酮 (5S)-6,6-二甲基-5-苄基-3-吗啉酮 (4-甲基-4H-呋喃并[3,2-b]吡咯-5-基)甲醇 (3aR,6aR)-4-乙酰基六氢-2H-呋喃并[3,2-b]吡咯-2-酮 (3AS,6AS)-六氢-2H-呋喃并[2,3-C]吡咯盐酸 4-(4-(4-methoxy-1H-pyrazolo[4,3-c]pyridin3-yl)pyridin-2-yl)-2,6-dimethylmorpholine 6-(N-Methyl-N-propargyl-aminomethyl)-benzofuran [Cu(2-(benzo[d]oxazol-2-yl)-4-iodophenol(1-))2] (3aR,6R,9R,10aR,10bS)-1,3-dioxo-6-pentyl-2,3,3a,4,6,8,9,10,10a,10b-decahydro-1H-oxepino[4,3-e]isoindol-9-yl morpholine-4-carboxylate 2,3,5-Trimethyl-7H-furo[2',3':4,5]pyrrolo[1,2-d][1,2,4]triazine-8-thione (3S*,4R*)-4-allyl-1-tert-butyldimethylsilyl-3-(4-methyl-2-oxo-1,3-dioxolan-4-yl)-2-azetidinone (2aR,4aS,5R,8R,8aR,8bS,12aS)-8-(tert-butyldimethylsiloxy)decahydro-5-hydroxy-2,2,4a-trimethyl-9H,12aH-naphtho[1',2':3,4]furo[2,3-b]pyran-4(2H)-one